Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 5 (May)

1. Ceramide synthases and ceramide levels are increased in breast cancer tissue.
   Carcinogenesis, 30(5): 745-52. [Abstract] [Full-text]
2. Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk.
   Carcinogenesis, 30(5): 777-84. [Abstract] [Full-text]
3. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study.
   Am J Epidemiol, 169(10): 1251-9. [Abstract] [Full-text]
4. Breast and prostate cancer survival in Michigan: can geographic analyses assist in understanding racial disparities?
   Cancer, 115(10): 2212-21. [Abstract] [Full-text]
5. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.
   Cancer, 115(10): 2041-51. [Abstract] [Full-text]
6. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
   Cancer, 115(10): 2222-33. [Abstract] [Full-text]
7. Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer.
   Eur J Surg Oncol, 35(6): 583-7. [Abstract] [Full-text]
8. The diagnostic value of nipple discharge cytology in 618 consecutive patients.
   Eur J Surg Oncol, 35(6): 573-7. [Abstract] [Full-text]
9. Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group.
   Eur J Surg Oncol, 35(6): 578-82. [Abstract] [Full-text]
10. Greater vegetable and fruit intake is associated with a lower risk of breast cancer among Chinese women.
    Int J Cancer, 125(1): 181-8. [Abstract] [Full-text]
11. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.
    Int J Cancer, 125(1): 9-14. [Abstract] [Full-text]
12. Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women.
    Int J Cancer, 125(1): 153-7. [Abstract] [Full-text]
13. Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia.
    Cancer Lett, 279(1): 108-17. [Abstract] [Full-text]
14. Do all patients of breast carcinoma need 3-dimensional CT-based planning? A dosimetric study comparing different breast sizes.
    Med Dosim, 34(2): 140-4. [Abstract] [Full-text]
15. Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions.
    Med Dosim, 34(2): 126-32. [Abstract] [Full-text]
16. Mammographically non-calcified ductal carcinoma in situ: sonographic features with pathological correlation in 35 patients.
    Clin Radiol, 64(6): 628-36. [Abstract] [Full-text]
17. Method of breast cancer presentation and depressed mood 1 year after diagnosis in women with locally advanced disease.
    Ann Surg Oncol, 16(6): 1637-41. [Abstract] [Full-text]
18. Percutaneous needle biopsy for breast diagnosis: how do surgeons decide?
    Ann Surg Oncol, 16(6): 1629-36. [Abstract] [Full-text]
19. Preparation and quality test of superparamagnetic iron oxide labeled antisense oligodeoxynucleotide probe: a preliminary study.
    Ann Biomed Eng, 37(6): 1240-50. [Abstract] [Full-text]
20. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
    Ann Surg Oncol, 16(6): 1619-28. [Abstract] [Full-text]
21. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy.
    Ann Surg Oncol, 16(6): 1597-605. [Abstract] [Full-text]
22. Local control, toxicity, and cosmesis in women younger than 50 enrolled onto the American Society of Breast Surgeons MammoSite Radiation Therapy System registry trial.
    Ann Surg Oncol, 16(6): 1612-8. [Abstract] [Full-text]
23. Separation of malignant human breast cancer epithelial cells from healthy epithelial cells using an advanced dielectrophoresis-activated cell sorter (DACS).
    Anal Bioanal Chem, 394(3): 801-9. [Abstract] [Full-text]
24. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
    Ann Surg Oncol, 16(6): 1606-11. [Abstract] [Full-text]
25. Caspase- and p53-dependent apoptosis in breast carcinoma cells induced by a synthetic selenadiazole derivative.
    Chem Biol Interact, 180(1): 54-60. [Abstract] [Full-text]
26. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    J Natl Cancer Inst, 101(9): 644-50. [Abstract] [Full-text]
27. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations.
    J Natl Cancer Inst, 101(9): 630-43. [Abstract] [Full-text]
28. ERalpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells.
    Proc Natl Acad Sci U S A, 106(18): 7420-5. [Abstract] [Full-text]
29. TrkA overexpression enhances growth and metastasis of breast cancer cells.
    Oncogene, 28(18): 1960-70. [Abstract] [Full-text]
30. Induction of cell cycle arrest in human MCF-7 breast cancer cells by cis-stilbene derivatives related to VIOXX.
    Toxicol Lett, 186(2): 115-22. [Abstract] [Full-text]
31. Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.
    Toxicology, 259(1): 25-32. [Abstract] [Full-text]
32. Quality of life after breast cancer surgery: What have we learned and where should we go next?
    J Surg Oncol, 99(7): 447-55. [Abstract] [Full-text]
33. The outcome of sentinel node biopsy in breast cancer patients with preoperative surgical biopsy.
    J Surg Oncol, 99(7): 420-3. [Abstract] [Full-text]
34. Population-based study of trends and variations in radiotherapy as part of primary treatment of cancer in the southern Netherlands between 1988 and 2006, with an emphasis on breast and rectal cancer.
    Int J Radiat Oncol Biol Phys, 74(2): 464-71. [Abstract] [Full-text]
35. Planning the breast boost: comparison of three techniques and evolution of tumor bed during treatment.
    Int J Radiat Oncol Biol Phys, 74(2): 458-63. [Abstract] [Full-text]
36. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up.
    Int J Radiat Oncol Biol Phys, 74(2): 447-52. [Abstract] [Full-text]
37. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis.
    Int J Radiat Oncol Biol Phys, 74(2): 440-6. [Abstract] [Full-text]
38. A long-term study of radiation therapy in t1-2 node-negative breast cancer patients in relation to the number of axillary nodes examined.
    Int J Radiat Oncol Biol Phys, 74(2): 453-7. [Abstract] [Full-text]
39. A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.
    Biochem Pharmacol, 77(12): 1787-94. [Abstract] [Full-text]
40. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment.
    Semin Cancer Biol, 19(3): 165-71. [Abstract] [Full-text]
41. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.
    J Pathol, 218(2): 265-72. [Abstract] [Full-text]
42. Protein kinases C isozymes are differentially expressed in human breast carcinomas.
    Life Sci, 84(21): 766-71. [Abstract] [Full-text]
43. Protective role of estrogen receptor-alpha on lower chlorinated PCB congener-induced DNA damage and repair in human tumoral breast cells.
    Toxicol Lett, 188(1): 11-9. [Abstract] [Full-text]
44. Effect of surface charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein endothelial cells.
    Colloids Surf B Biointerfaces, 71(2): 325-30. [Abstract] [Full-text]
45. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer.
    Br J Cancer, 100(10): 1687-96. [Abstract] [Full-text]
46. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.
    Br J Cancer, 100(10): 1680-6. [Abstract] [Full-text]
47. Adjuvant chemotherapy in older women with early-stage breast cancer.
    N Engl J Med, 360(20): 2055-65. [Abstract] [Full-text]
48. Artemin is oncogenic for human mammary carcinoma cells.
    Oncogene, 28(19): 2034-45. [Abstract] [Full-text]
49. Mucoepidermoid carcinoma of the breast shares cytogenetic abnormality with mucoepidermoid carcinoma of the salivary gland: a case report with molecular analysis and review of the literature.
    Hum Pathol, 40(6): 887-92. [Abstract] [Full-text]
50. Isolated tumor cells in breast cancer sentinel lymph nodes: displacement or metastases? An immunohistochemical study.
    Hum Pathol, 40(6): 778-82. [Abstract] [Full-text]
51. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
    Lancet, 373(9676): 1681-92. [Abstract] [Full-text]
52. Molecular mechanisms controlling E-cadherin expression in breast cancer.
    Biochem Biophys Res Commun, 384(1): 6-11. [Abstract] [Full-text]
53. Metabolism of histamine in tissues of primary ductal breast cancer.
    Metabolism, 58(6): 867-70. [Abstract] [Full-text]
54. Mucinous breast carcinoma with myoepithelial-like spindle cells.
    Diagn Cytopathol, 37(6): 393-6. [Abstract] [Full-text]
55. Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice.
    Clin Immunol, 131(3): 426-37. [Abstract] [Full-text]
56. Comparison of accuracy of diagnostic modalities for evaluation of breast cancer with review of literature.
    Diagn Cytopathol, 37(6): 416-24. [Abstract] [Full-text]
57. BRCA1 involvement in toxicological responses and human cancer etiology.
    Toxicol Lett, 188(2): 77-83. [Abstract] [Full-text]
58. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary.
    Mol Cell, 34(3): 271-84. [Abstract] [Full-text]
59. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study.
    J Clin Oncol, 27(15): 2482-8. [Abstract] [Full-text]
60. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer.
    J Clin Oncol, 27(15): 2466-73. [Abstract] [Full-text]
61. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
    J Clin Oncol, 27(15): 2474-81. [Abstract] [Full-text]
62. Silencing of Kv4.1 potassium channels inhibits cell proliferation of tumorigenic human mammary epithelial cells.
    Biochem Biophys Res Commun, 384(2): 180-6. [Abstract] [Full-text]
63. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    J Natl Cancer Inst, 101(10): 736-50. [Abstract] [Full-text]
64. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.
    J Natl Cancer Inst, 101(10): 729-35. [Abstract] [Full-text]
65. Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells.
    Cancer Lett, 280(1): 110-9. [Abstract] [Full-text]
66. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo.
    Cancer Lett, 280(1): 31-7. [Abstract] [Full-text]
67. Heregulin-beta1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of Snail and induction of epithelial-mesenchymal transition.
    Cancer Lett, 280(1): 50-60. [Abstract] [Full-text]
68. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
    AJR Am J Roentgenol, 192(6): 1608-17. [Abstract] [Full-text]
69. Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study.
    Am J Clin Nutr, 89(6): 1920-6. [Abstract] [Full-text]
70. Minireview: Obesity and breast cancer: the estrogen connection.
    Endocrinology, 150(6): 2537-42. [Abstract] [Full-text]
71. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
    Proc Natl Acad Sci U S A, 106(20): 8368-73. [Abstract] [Full-text]
72. A review on bevacizumab and surgical wound healing: an important warning to all surgeons.
    Ann Plast Surg, 62(6): 707-9. [Abstract] [Full-text]
73. Decreased narcotic use with an implantable local anesthetic catheter after deep inferior epigastric perforator flap breast reconstruction.
    Ann Plast Surg, 62(6): 618-20. [Abstract] [Full-text]
74. Familial risk for common diseases in primary care: the Family Healthware Impact Trial.
    Am J Prev Med, 36(6): 506-14. [Abstract] [Full-text]
75. Impact of mailed and automated telephone reminders on receipt of repeat mammograms: a randomized controlled trial.
    Am J Prev Med, 36(6): 459-67. [Abstract] [Full-text]
76. ACOG Committee Opinion No. 434: induced abortion and breast cancer risk.
    Obstet Gynecol, 113(6): 1417-8. [Abstract] [Full-text]
77. Clinicopathologic implications of "flat epithelial atypia" in core needle biopsy specimens of the breast.
    Am J Clin Pathol, 131(6): 802-8. [Abstract] [Full-text]
78. Hair iron and other minerals' level in breast cancer patients.
    Biol Trace Elem Res, 129(1): 28-35. [Abstract] [Full-text]
79. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth.
    Biochem Biophys Res Commun, 384(3): 329-33. [Abstract] [Full-text]
80. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.
    Cancer Treat Rev, 35(4): 328-34. [Abstract] [Full-text]
81. Quis custodiet ipsos custodies: who watches the watchmen?
    Am J Pathol, 174(6): 1996-9. [Abstract] [Full-text]
82. Stromal cell expression of caveolin-1 predicts outcome in breast cancer.
    Am J Pathol, 174(6): 2035-43. [Abstract] [Full-text]
83. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
    Am J Pathol, 174(6): 2023-34. [Abstract] [Full-text]
84. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.
    Ann Oncol, 20(6): 1013-9. [Abstract] [Full-text]
85. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
    Ann Oncol, 20(6): 1026-31. [Abstract] [Full-text]
86. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial.
    Ann Oncol, 20(6): 1001-7. [Abstract] [Full-text]
87. High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer.
    Ann Oncol, 20(6): 977-84. [Abstract] [Full-text]
88. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
    Ann Oncol, 20(6): 993-9. [Abstract] [Full-text]
89. Unavoidable mastectomy for ipsilateral breast tumour recurrence after conservative surgery: patient outcome.
    Ann Oncol, 20(6): 1008-12. [Abstract] [Full-text]
90. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer.
    Ann Oncol, 20(6): 1020-5. [Abstract] [Full-text]
91. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis.
    Eur J Surg Oncol, 35(7): 690-5. [Abstract] [Full-text]
92. Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection--data from a prospective randomised trial.
    Eur J Surg Oncol, 35(7): 696-701. [Abstract] [Full-text]
93. Parity in relation to survival following breast cancer.
    Eur J Surg Oncol, 35(7): 702-8. [Abstract] [Full-text]
94. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.
    Hum Mol Genet, 18(12): 2297-304. [Abstract] [Full-text]
95. Estrogen receptor beta in breast cancer--diagnostic and therapeutic implications.
    Steroids, 74(8): 635-41. [Abstract] [Full-text]
96. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.
    Cancer Immunol Immunother, 58(8): 1185-94. [Abstract] [Full-text]
97. Systematic identification of transcription factors associated with patient survival in cancers.
    BMC Genomics, 10: 225. [Abstract] [Full-text]
98. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Arch Gynecol Obstet, 280(1): 43-8. [Abstract] [Full-text]
99. Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma.
    Arch Gynecol Obstet, 280(1): 149-52. [Abstract] [Full-text]
100. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?
     Br J Cancer, 100(11): 1806-11. [Abstract] [Full-text]
101. Can compression be reduced for breast tomosynthesis? Monte carlo study on mass and microcalcification conspicuity in tomosynthesis.
     Radiology, 251(3): 673-82. [Abstract] [Full-text]
102. HER-2/neu analysis in breast cancer bone metastases.
     J Clin Pathol, 62(6): 542-6. [Abstract] [Full-text]
103. Probabilistic computer model developed from clinical data in national mammography database format to classify mammographic findings.
     Radiology, 251(3): 663-72. [Abstract] [Full-text]
104. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
     Radiology, 251(3): 653-62. [Abstract] [Full-text]
105. Sentinel lymph node biopsy in patients with a needle core biopsy diagnosis of ductal carcinoma in situ: is it justified?
     J Clin Pathol, 62(6): 534-8. [Abstract] [Full-text]
106. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
     Breast Cancer Res Treat, 115(3): 661-8. [Abstract] [Full-text]
107. Cyclin E deregulation is an early event in the development of breast cancer.
     Breast Cancer Res Treat, 115(3): 651-9. [Abstract] [Full-text]
108. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
     Breast Cancer Res Treat, 115(3): 643-50. [Abstract] [Full-text]
109. Acupuncture for treating hot flashes in breast cancer patients: a systematic review.
     Breast Cancer Res Treat, 115(3): 497-503. [Abstract] [Full-text]
110. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?
     Breast Cancer Res Treat, 115(3): 453-95. [Abstract] [Full-text]
111. Use of antioxidant supplements during breast cancer treatment: a comprehensive review.
     Breast Cancer Res Treat, 115(3): 437-52. [Abstract] [Full-text]
112. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
     Breast Cancer Res Treat, 115(3): 609-12. [Abstract] [Full-text]
113. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy.
     Breast Cancer Res Treat, 115(3): 601-8. [Abstract] [Full-text]
114. Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch BLN Assay in the operating room: results of the Cardiff study.
     Breast Cancer Res Treat, 115(3): 595-600. [Abstract] [Full-text]
115. Weekly epirubicin in the treatment of gestational breast cancer (GBC).
     Breast Cancer Res Treat, 115(3): 591-4. [Abstract] [Full-text]
116. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
     Breast Cancer Res Treat, 115(3): 581-90. [Abstract] [Full-text]
117. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study.
     Breast Cancer Res Treat, 115(3): 573-80. [Abstract] [Full-text]
118. Autoimmune hypothyroidism and breast cancer in the elderly.
     Breast Cancer Res Treat, 115(3): 635-41. [Abstract] [Full-text]
119. Vitamin D receptor variants and breast cancer risk in the Polish population.
     Breast Cancer Res Treat, 115(3): 629-33. [Abstract] [Full-text]
120. Calmodulin modulates Akt activity in human breast cancer cell lines.
     Breast Cancer Res Treat, 115(3): 545-60. [Abstract] [Full-text]
121. Columnar cell lesions, mammographic density and breast cancer risk.
     Breast Cancer Res Treat, 115(3): 561-71. [Abstract] [Full-text]
122. Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population.
     Breast Cancer Res Treat, 115(3): 537-43. [Abstract] [Full-text]
123. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo).
     Breast Cancer Res Treat, 115(3): 505-21. [Abstract] [Full-text]
124. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients.
     Breast Cancer Res Treat, 115(3): 523-35. [Abstract] [Full-text]
125. DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.
     Breast Cancer Res Treat, 115(3): 623-7. [Abstract] [Full-text]
126. Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk.
     Breast Cancer Res Treat, 115(3): 613-22. [Abstract] [Full-text]
127. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.
     J Neurooncol, 93(3): 379-84. [Abstract] [Full-text]
128. Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
     Cancer Invest, 27(5): 521-8. [Abstract] [Full-text]
129. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
     Cancer Invest, 27(5): 489-95. [Abstract] [Full-text]
130. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
     J Clin Oncol, 27(16): 2630-7. [Abstract] [Full-text]
131. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
     J Clin Oncol, 27(16): 2638-44. [Abstract] [Full-text]
132. Toward a stem cell gene therapy for breast cancer.
     Blood, 113(22): 5423-33. [Abstract] [Full-text]
133. Cross-talk between Notch and EGFR signaling in human breast cancer cells.
     Cancer Invest, 27(5): 533-40. [Abstract] [Full-text]
134. Expression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil.
     Cancer Invest, 27(5): 561-7. [Abstract] [Full-text]
135. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
     Clin Chim Acta, 404(2): 160-5. [Abstract] [Full-text]
136. Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas.
     Clin Chim Acta, 404(2): 111-8. [Abstract] [Full-text]

© 2004-2010 Breast Cancer Research Today. All Rights Reserved.